The vulnerability could allow attackers to execute arbitrary commands and steal credentials and other secrets. A critical sandbox escape vulnerability in the n8n AI workflow automation platform could ...
Multiple critical vulnerabilities in the popular n8n open-source workflow automation platform allow escaping the confines of the environment and taking complete control of the host server.
A JavaScript sandbox bug rated CVSS 9.9 enables attackers to bypass AST‑based protections, while a Python execution bypass affects internal‑mode deployments common in enterprise setups. Two critical ...
Public charter operator JSX has formally marked the introduction into service of its first ATR 42-600 turboprop, an aircraft the carrier says will play a major role in its future operations. Dallas, ...
Private charter carrier JSX to fly to Las Vegas and Scottsdale from history Santa Monica Airport, buy up to 30 of the populaar ATR turboprops for use from smaller airports. An ATR turboprop in JSX ...
Starting tomorrow, December 19, 2025, commercial aviation will return to Santa Monica, California (SMO), when JSX commences flights to Las Vegas (LAS). But, just a day before that service starts, JSX ...
A critical vulnerability in the popular expr-eval JavaScript library, with over 800,000 weekly downloads on NPM, can be exploited to execute code remotely through maliciously crafted input. The ...
Instant experiences on the web have become more of a requirement than a preference. The performance of React applications depends heavily on JavaScript bundle size ...
Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Navigate today’s economy with helpful tips + enter our $26K ...
If you purchase an independently reviewed product or service through a link on our website, Variety may receive an affiliate commission. Air carrier JSX is now flying to Napa, just in time for harvest ...
A comparative study of the real-world safety and effectiveness of metronomic cyclophosphamide and bevacizumab with or without pembrolizumab for recurrent ovarian cancer. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results